Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2GPD2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Metformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metformin SCHEMBL1747396 | 0.97 | HTT (0.37) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL1766280 | 0.97 | LMNA (0.36) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL8944 | 0.97 | — | — | |
| Metformin SCHEMBL18953625 | 0.94 | HTT (0.39) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL1560020 | 0.94 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL433864 | 0.94 | HTT (0.39) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL1290484 | 0.94 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL22127017 | 0.94 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL1333960 | 0.94 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL4421557 | 0.94 | HTT (0.39) | LMNADPP4ADRA1AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | claimed |
| US-20130217749-A1 | MODULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE-MITCHONDRIAL (PEPCK-M) EXPRESSION | YALE UNIVERSITY (US) | 2013-08-22 | — | — | US | claimed |
| EP-2521556-A2 | MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION | Isis Pharmaceuticals, Inc. (US) | 2012-11-14 | — | — | EP | claimed |
| WO-2011127175-A1 | MODULATION OF CD130 (GP130) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | claimed |
| WO-2011085271-A2 | MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| EP-2294181-A2 | MODULATION OF SMRT EXPRESSION | Isis Pharmaceuticals, Inc. (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2294213-A2 | METHODS FOR MODULATING EXPRESSION OF CREB | Isis Pharmaceuticals, Inc. (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2291200-A2 | METHODS FOR MODULATING EXPRESSION OF RBP4 | Isis Pharmaceuticals, Inc. (US) | 2011-03-09 | — | — | EP | claimed |
| WO-2010090830-A1 | MODULATION OF SIRT1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | claimed |
| WO-2009143387-A2 | MODULATION OF SMRT EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| WO-2009143463-A2 | METHODS FOR MODULATING EXPRESSION OF CREB | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| WO-2009143391-A2 | METHODS FOR MODULATION EXPRESSION OF CREB | ISIS PHARMACEUTICALS, INC (US) | 2009-11-26 | — | — | WO | claimed |
| WO-2009143390-A2 | METHODS FOR MODULATING EXPRESSION OF RBP4 | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| US-20060089325-A1 | Antisense modulation of PTP1B expression | ISIS PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | claimed |
| WO-2006032042-A2 | US OF CNTF OR A CNTF DERIVATIVE IN COMBINATION WITH A FURTHER COMPOUND FOR THE PREPARATION OF MEDICAMENT FOR THE TREATMENT OF OBESITY | REGENERON PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | claimed |
| US-20060058224-A1 | Methods of treating obesity with combination therapeutics | REGENERON PHARMACEUTICALS, INC. | 2006-03-16 | — | — | US | claimed |
| WO-2005065675-A1 | METHOD OF TREATMENT | PREMACS INTERNATIONAL PTY. LTD. (AU) | 2005-07-21 | — | — | WO | claimed |
| US-6548481-B1 | Effectors of dipeptidyl peptidase IV | PROBIODRUG AG (DE) | 2003-04-15 | — | — | US | claimed |
| US-12031137-B2 | Compositions comprising SASP modulators and senescence attenuators and uses thereof for modulating cellular senescence | RSEM, LIMITED PARTNERSHIP (CA) | 2024-07-09 | — | — | US | disclosed |
| WO-1992003148-A1 | IMPROVED HYPOGLYCEMICS | AMYLIN CORPORATION (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | LMNA 3314/4885DPP4 4670/4885ADRA1A 844/4885 |
| US-20130217749-A1 | MODULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE-MITCHONDRIAL (PEPCK-M) EXPRESSION | PCK2, PCK1, PC | LMNA 1189/4885DPP4 360/4885ADRA1A 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.